Madam Therapeutics
Biotech startup, developing sustainable, pragmatic solutions to alleviate the burden of infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €1.1m | Seed | |
| Total Funding | 000k | ||
Related Content
Madam Therapeutics is a biotechnology company focused on developing next-generation anti-infectives to combat global antimicrobial resistance. The company operates in the pharmaceutical and healthcare market, targeting healthcare providers, hospitals, and patients affected by resistant infections. Madam Therapeutics' business model revolves around the research, development, and commercialization of novel antibiotics. The company generates revenue through the sale of its proprietary drugs and potential licensing agreements with larger pharmaceutical firms. By addressing the critical need for new antibiotics, Madam Therapeutics aims to significantly reduce the mortality rate associated with resistant infections, which currently claims 700,000 lives annually and could rise to 10 million by 2050. The company's innovative approach and commitment to the One Health philosophy underscore its dedication to improving global health outcomes.
Keywords: biotechnology, anti-infectives, antimicrobial resistance, novel antibiotics, healthcare, pharmaceutical, research, development, commercialization, One Health.